Financhill
Sell
39

XTNT Quote, Financials, Valuation and Earnings

Last price:
$0.66
Seasonality move :
-3.57%
Day range:
$0.64 - $0.68
52-week range:
$0.33 - $0.83
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.77x
P/B ratio:
2.19x
Volume:
17.4K
Avg. volume:
74.7K
1-year change:
-0.77%
Market cap:
$95.9M
Revenue:
$117.3M
EPS (TTM):
-$0.09

Analysts' Opinion

  • Consensus Rating
    Xtant Medical Holdings has received a consensus rating of No Consensus. The company's average rating is a No Consensus based on 1 Buy rating, 0 Hold ratings, and 1 Sell rating.
  • Price Target Upside
    According to analysts' consensus price target of $1.75, Xtant Medical Holdings has an estimated upside of 154.18% from its current price of $0.66.
  • Price Target Downside
    According to analysts, the lowest downside price target is $1.50 representing -117.87% downside risk from its current price of $0.66.

Fair Value

  • According to the consensus of 2 analysts, Xtant Medical Holdings has 154.18% upside to fair value with a price target of $1.75 per share.

XTNT vs. S&P 500

  • Over the past 5 trading days, Xtant Medical Holdings has underperformed the S&P 500 by -0.67% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Xtant Medical Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Xtant Medical Holdings has grown year-over-year revenues for 13 quarters straight. In the most recent quarter Xtant Medical Holdings reported revenues of $32.9M.

Earnings Growth

  • Xtant Medical Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Xtant Medical Holdings reported earnings per share of --.
Enterprise value:
124.3M
EV / Invested capital:
--
Price / LTM sales:
0.77x
EV / EBIT:
--
EV / Revenue:
1.02x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-13.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
55.58x
Gross Profit (TTM):
$71.2M
Return On Assets:
-12.54%
Net Income Margin (TTM):
-9.81%
Return On Equity:
-26.62%
Return On Invested Capital:
-15.44%
Operating Margin:
3.23%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue $63M $101.2M $122.3M $27.9M $32.9M
Gross Profit $35.1M $62.2M $71.2M $17.3M $20.2M
Operating Income -$6.5M -$12.1M -$7.5M -$3.5M $1.1M
EBITDA -$4.9M $3.6M -$3.2M -$2.5M $2.2M
Diluted EPS -$0.09 -$0.01 -$0.09 -$0.03 --
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $48.5M $42.8M $36.6M $66.5M $69.1M
Total Assets $58.7M $53.2M $63.3M $93.9M $95.8M
Current Liabilities $24M $11.2M $17.3M $28.4M $29.6M
Total Liabilities $25.3M $23.9M $30.6M $46.3M $52M
Total Equity $33.4M $29.3M $32.7M $47.7M $43.9M
Total Debt $16.5M $15.5M $20M $27.1M $33.4M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$6.6M -$13M -$4.9M -$5.8M $1.3M
Cash From Investing -$18.6M -$8M -$4.2M -$674K -$1.1M
Cash From Financing $13.6M $20.3M $10M $5.2M -$919K
Free Cash Flow -$8.3M -$14.8M -$9.4M -$6.5M $87K
XTNT
Sector
Market Cap
$95.9M
$33.5M
Price % of 52-Week High
82.7%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.97%
1-Year Price Total Return
2.76%
-33.61%
Beta (5-Year)
-0.139
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $0.68
200-day SMA
Buy
Level $0.54
Bollinger Bands (100)
Buy
Level 0.46 - 0.66
Chaikin Money Flow
Sell
Level -286.7K
20-day SMA
Buy
Level $0.65
Relative Strength Index (RSI14)
Buy
Level 50.46
ADX Line
Sell
Level 21.54
Williams %R
Neutral
Level -45.202
50-day SMA
Buy
Level $0.63
MACD (12, 26)
Buy
Level 0.15
25-day Aroon Oscillator
Buy
Level 28
On Balance Volume
Sell
Level -252.2K

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-1.8276)
Sell
CA Score (Annual)
Level (-0.5293)
Buy
Beneish M-Score (Annual)
Level (-2.7687)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (1.6348)
Sell
Piotroski F Score (Annual)
Level (3)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

Stock Forecast FAQ

In the current month, XTNT has received 1 Buy ratings 0 Hold ratings, and 1 Sell ratings. The XTNT average analyst price target in the past 3 months is $1.75.

  • Where Will Xtant Medical Holdings Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Xtant Medical Holdings share price will rise to $1.75 per share over the next 12 months.

  • What Do Analysts Say About Xtant Medical Holdings?

    Analysts are divided on their view about Xtant Medical Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xtant Medical Holdings is a Sell and believe this share price will drop from its current level to $1.50.

  • What Is Xtant Medical Holdings's Price Target?

    The price target for Xtant Medical Holdings over the next 1-year time period is forecast to be $1.75 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is XTNT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Xtant Medical Holdings is a No Consensus. 1 of 2 analysts rates the stock a No Consensus at this time.

  • How Can I Buy Shares Of XTNT?

    You can purchase shares of Xtant Medical Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xtant Medical Holdings shares.

  • What Is The Xtant Medical Holdings Share Price Today?

    Xtant Medical Holdings was last trading at $0.66 per share. This represents the most recent stock quote for Xtant Medical Holdings. Yesterday, Xtant Medical Holdings closed at $0.66 per share.

  • How To Buy Xtant Medical Holdings Stock Online?

    In order to purchase Xtant Medical Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

What Is the Ceiling for IONQ Stock?
What Is the Ceiling for IONQ Stock?

IonQ (NYSE:IONQ) is a quantum computing startup that, like many…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock